)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Dimerix
Dimerix (DXB) investor relations material
Dimerix Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary28 Oct, 2026
Executive summary
September quarter strengthened funding, advanced DMX-200 Phase 3 and added DMX-652, a Phase 2-ready acute kidney injury asset.
The Everest Medicines agreement was the fifth regional DMX-200 licence; upfront receipts across five agreements exceed A$80 million, with potential milestones of ~A$1.9 billion plus royalties.
Financial highlights
Cash and cash equivalents rose to A$34.843 million at 30 September 2026 from A$16.154 million at 30 June 2026.
Operating activities generated A$9.048 million net cash in the quarter, including A$14.146 million customer receipts and A$5.172 million R&D payments.
Investing activities used A$7.138 million; financing activities generated A$16.656 million, including A$16.685 million borrowing proceeds.
Reported cash receipts included the A$14.1 million Everest upfront payment; the quarter also included an approximately US$5 million upfront fee to acquire DMX-652.
Outlook and guidance
Funding is stated to cover completion of ACTION3 Phase 3 and continued advancement of the DMX-652 Phase 2 program.
DMX-200 ACTION3 final proteinuria endpoint is targeted for H1 2028; potential 2028 milestones include Phase 3 readout and NDA dossier submission.
DMX-652 plans include Phase 2 initiation in 2026, first patient dosing and interim analysis in 2027, and Phase 2 readout and Phase 3 preparation in 2028.
DMX-652 cash requirements are expected to remain modest near term; ACTION3 expenditure is expected to decrease as participants complete the trial.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Dimerix
- Late-stage kidney disease pipeline and global partnerships drive up to $1.9B revenue potential.DXB
Investor presentation - Advanced kidney disease pipeline with global partnerships and major late-stage clinical milestones.DXBInvestor presentation
- Late-stage kidney disease pipeline with global deals and strong IP drives diversified growth.DXBInvestor presentation
- Net loss rose to $29.8M on higher R&D, with major licensing and pipeline expansion achieved.DXBH2 2026
- Advancing kidney disease therapies with global deals and a diversified, risk-managed approach.DXBInvestor presentation
- Phase 3 FSGS trial fully recruited; DMX-652 phase 2 ready; global deals up to AU$1.9B.DXBInvestor presentation
- DMX-200 advances in global FSGS trials, securing major licensing deals and strong market potential.DXBInvestor presentation
- Strong licensing income, robust cash reserves, and global trial progress position for future growth.DXBH2 2025
- DMX-200 Phase 3 advances, major licensing deals, and strong cash position despite higher R&D loss.DXBH2 2024
Next Dimerix earnings date
H1 202724 Feb, 2027
Dimerix
Next Dimerix earnings date
H1 202724 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Dimerix Limited is an Australian biopharmaceutical company focused on developing new therapies for rare and progressive diseases, particularly kidney and inflammatory diseases. The company’s lead candidate targets chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS) and diabetic kidney disease, using a proprietary drug discovery and development platform. Dimerix applies receptor-based science to create treatments that address unmet medical needs in complex diseases with few current therapeutic options. The company is involved in clinical trials to advance its drug candidates towards regulatory approval. The company is headquartered in Melbourne, Victoria, and its shares are listed on the ASX.